BACKBEAT Pivotal Trial Surpasses Full Enrollment: A Defining Milestone for AVIM Therapy
Orchestra BioMed Investor Relations Blog | October 2026
News & Events
Oct 8, 2026, 11:59:09 AM / by Orchestra BioMed posted in Clinical
Orchestra BioMed Investor Relations Blog | October 2026
Apr 28, 2026, 10:57:42 AM / by Orchestra BioMed posted in Clinical
Orchestra BioMed Investor Relations Blog | April 2026
Recently presented clinical and mechanistic findings reinforce the potential of Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) to immediately reduce blood pressure and have a favorable cardiac hemodynamic impact, expanding its potential therapeutic relevance beyond hypertension into hypertensive heart disease.
Mar 24, 2026, 1:09:24 PM / by Orchestra BioMed posted in Clinical
Orchestra BioMed recently announced multiple scientific presentations highlighting the robust body of existing clinical findings from the Atrioventricular Interval Modulation (“AVIM”) Therapy program at the Technology Heart Failure and Therapeutics (“THT”) and Cardiovascular Research Technologies (“CRT”) 2026 Meetings. These discussions reinforce growing clinical interest in our novel, device-based approach to treating hypertension and reducing associated cardiovascular risk.
Dec 15, 2025, 11:00:00 AM / by Orchestra BioMed posted in Clinical
This week, at the Innovation in Cardiovascular Intervention (“ICI”) meeting in Israel, Orchestra BioMed highlighted the strategic and clinical progress behind its two pivotal programs - Atrioventricular Interval Modulation Therapy (“AVIM Therapy”)and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”).
Nov 24, 2025, 11:00:00 AM / by Orchestra BioMed posted in Clinical
This post is Part 2 of 2 in our summary of Chairman and CEO David Hochman’s recent shareholder update call, which provided a detailed perspective on Orchestra BioMed’s progress through 2025.
Nov 18, 2025, 1:57:25 PM / by Orchestra BioMed posted in Clinical
Sep 22, 2025, 12:30:00 AM / by Orchestra BioMed posted in Clinical
AVIM therapy: Durability, Reversibility, and Reproducibility of Effect
Recent clinical announcements related to our AVIM therapy program address three primary questions:
The August 14 publication in JACC: Advances focused on echocardiographic measures of cardiac function in patients with diastolic dysfunction. The later August publication in JACC: Clinical Electrophysiology analyzed the positive impact of AVIM therapy on blood pressure and cardiac hemodynamics using invasive and noninvasive pressure–volume (PV) loop measurements, considered by many to be the “gold standard” for comprehensive assessment of the activity of the heart. These AVIM therapy results were also assessed using standard pacing lead placement as well as lead placements intended to achieve conduction system pacing in the same patients. Conduction system pacing is a more advanced approach to cardiac pacing that is considered potentially safer and more effective and is rapidly being adopted by electrophysiologists. Most recently, our team presented data from a long-term washout study at the HRX Live 2025 Meeting (“HRX”), along with a summary of the technology simultaneously published in the peer-reviewed Heart Rhythm O2 journal.
At HRX, long-term follow-up from MODERATO II showed that, in a chronically-treated cohort of patients (n=16), 24-hour ambulatory systolic blood pressure (aSBP) reductions were sustained on therapy over a mean of 3.6 years (average change –8.9 mmHg; p<0.001). When AVIM was deactivated, aSBP returned to baseline with no evidence of rebound hypertension.
After a 7-day washout period, reactivation was associated with an immediate reduction in aSBP (p<0.002), to levels similar to prior on-therapy measurements - supporting reproducibility of effect.
— Team OBIO
Certain statements included in the content distributed by Orchestra BioMed Holdings, Inc. (the “Company”) to which this disclaimer relates (including, but not limited to, visual, auditory, or written statements) (the “Content”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the initiation, enrollment, timing, implementation and design of the Company’s planned and ongoing pivotal trials, the potential benefits of regulatory approvals or designations received from domestic and foreign regulatory bodies with respect to the Company’s product candidates and/or ongoing trials, the potential safety and efficacy of the Company’s product candidates, the ability of the Company’s partnerships to accelerate clinical development, the realization of the clinical and commercial value of the Company’s product candidates, and the Company’s ability to achieve expected regulatory and business milestones.. These statements are based on various assumptions, whether or not identified in the Content, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s annual report on Form 10-K filed with the SEC on March 31, 2025, and under the heading “Item 1A. Risk Factors” in the Company’s subsequently filed quarterly reports on Form 10-Q. The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of the Content. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made in the Content, except as required by law.
Jun 20, 2025, 4:30:00 AM / by Orchestra BioMed posted in Clinical
May 12, 2025, 4:30:00 AM / by Orchestra BioMed posted in Clinical
First Quarter 2025 Business Highlights
Orchestra BioMed has demonstrated good momentum so far in 2025 as we continue to execute on our mission of advancing high-impact cardiovascular innovations through strategic, capital-efficient partnerships.
Our two flagship programs – atrioventricular interval modulation (“AVIM”) therapy for hypertension and Virtue® Sirolimus AngioInfusion Balloon (“SAB”) for coronary artery disease - each achieved key U.S. Food and Drug Administration (“FDA”) and clinical milestones that deepen our conviction in their long-term potential.
Here are several highlights from our Q1 earnings announcement and business update that underscore our steady, value-focused approach:
David Hochman, OBIO’s Chairman and CEO, offered the following insights in this quarter’s update:
As we move deeper into 2025, OBIO remains focused on disciplined execution, strategic clinical advancement, and building durable shareholder value through a methodical, partnership-driven approach.
With multiple FDA milestones achieved, ongoing enrollment in a global pivotal study, and a growing body of supportive clinical data, we believe OBIO is well-positioned for long-term impact.
We appreciate your continued support and look forward to updating you on our progress.
— Team OBIO
© 2026 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01